A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Ocrelizumab (Primary) ; Diphenhydramine; Diphenhydramine; Methylprednisolone
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms MUSETTE
- Sponsors Roche
- 11 Mar 2024 Planned primary completion date changed from 3 Mar 2025 to 19 Dec 2024.
- 19 May 2023 Planned End Date changed from 30 Mar 2029 to 31 Aug 2028.
- 19 May 2023 Planned primary completion date changed from 18 Jul 2025 to 3 Mar 2025.